In a public/private partnership context, the “Resistance group” of  IMoST team and two biotechnology companies BIOPASS and BIOMARQUEURS work together in the BIORCELL 3D consortium. They focus their expertise on the development on biotechnology preclinical tools, useful for treatment optimization and diagnosis.

The team is specialized in 3D cell culture models from various cancer cell lines and / or transformed cells as preclinical tools which can be used in drug discovery and for new therapies development. The production of these models is optimized with the culture in more reproducible conditions thanks to serum-free OptiPASS® medium. This will also allow marketing development in the format of Opti3D kits. 

In an other part, this collaboration was the starting point of fluorescent probes development. For this, pharmacomodulation of existing or new drugs is made to study their penetration, distribution, binding and efflux. These steps can be carried out at the cellular level, or in 3D models and in tumoral biopsies. Other types of chemical biotrackers are synthetized to propose new diagnostic tests applied in human health and environment.